Optimize Medication by Increasing Mirtazapine to 30-45mg and Consider Switching or Augmenting with Bupropion
Given persistent depressive symptoms despite multiple medications, the most evidence-based approach is to optimize your current mirtazapine dose (currently subtherapeutic at 15mg) to 30-45mg daily, and strongly consider either switching to or augmenting with bupropion, which specifically targets the motivational and energy symptoms you're experiencing.
Current Regimen Analysis
Your current medications reveal several optimization opportunities:
Mirtazapine 15mg is below the therapeutic range - The FDA-approved dosing starts at 15mg but requires titration up to 45mg maximum for adequate antidepressant effect 1. At 15mg, you're receiving primarily sedating antihistamine effects without full noradrenergic and serotonergic benefits.
Ritalin 5mg once daily is a minimal dose - While methylphenidate can augment antidepressants for fatigue and motivation 2, your dose (5mg daily) is at the very bottom of the therapeutic range (typically 5-30mg/day divided doses). This may provide insufficient dopaminergic augmentation for your motivational symptoms.
Buspirone 15mg daily has limited evidence - When used as augmentation in treatment-resistant depression, buspirone showed no advantage over bupropion and had higher discontinuation rates due to adverse effects 3, 4.
Primary Recommendation: Mirtazapine Dose Optimization
Increase mirtazapine from 15mg to 30mg immediately, with potential further increase to 45mg after 1-2 weeks 1. The FDA label specifies dose changes should not occur more frequently than every 1-2 weeks. This optimization is critical because:
- You're currently receiving subtherapeutic dosing
- Higher doses (30-45mg) provide the full noradrenergic effects needed for motivation and energy
- Mirtazapine at proper doses showed effectiveness in treatment-resistant depression 5
Important caveat: If you have obesity (BMI ≥28) or are taking any CYP3A4 inhibitors, dose adjustments may need to be more conservative 6.
Secondary Recommendation: Address Motivational Symptoms
Your complaints of "hopelessness, lack of motivation, emotional outbursts" suggest inadequate treatment of specific symptom clusters. The evidence strongly supports:
Option A: Switch to Bupropion (Preferred)
- Bupropion specifically targets hypersomnia, low energy, increased appetite, and motivational deficits 7
- Starting dose: 37.5mg daily, increase by 37.5mg every 3 days to 150mg twice daily 8
- Bupropion is "activating" and provides "rapid improvement of energy level" 8
- Critical timing: Give second dose before 3pm to minimize insomnia 8
Option B: Augment with Bupropion
- If you want to maintain mirtazapine, augmentation with bupropion showed superiority over buspirone augmentation for weight, appetite, and fatigue symptoms 3, 7
- The combination of escitalopram + bupropion demonstrated complementary symptom-specific benefits in CO-MED trial 7
Methylphenidate Considerations
Your current Ritalin dose is inadequate. If continuing stimulant augmentation:
- Increase to 5mg twice daily (morning and lunch, no later than 2pm) 2, 9
- Maximum therapeutic range is 5-30mg/day divided 2
- Monitor for agitation and insomnia, which are most common side effects 2
However, consider discontinuing methylphenidate entirely if you switch to or augment with bupropion, as both provide dopaminergic activation and combining them increases risk without clear additional benefit.
Buspirone Reassessment
Strongly consider discontinuing buspirone 3, 4. The evidence shows:
- No difference in response or remission compared to bupropion augmentation 3
- Higher discontinuation rates due to adverse events compared to bupropion 3
- Takes 2-4 weeks to become effective and only useful in mild-moderate agitation 8
Your emotional outbursts may be better addressed by optimizing your primary antidepressant rather than continuing an anxiolytic with limited evidence in treatment-resistant depression.
Lamotrigine Continuation
Continue lamotrigine 150mg BID as prescribed. This provides mood stabilization and is appropriate given your history of treatment resistance and emotional dysregulation.
Monitoring and Timeline
Week 1-2:
- Increase mirtazapine to 30mg QHS
- Monitor for increased sedation (usually improves after first week)
- Assess response using standardized measure (PHQ-9 or similar)
Week 2-4:
- If inadequate response, increase mirtazapine to 45mg QHS 1
- Consider adding or switching to bupropion if motivational symptoms persist
Week 6-8:
- Reassess treatment response - guidelines mandate treatment modification if inadequate response by 6-8 weeks 10
- If still inadequate, implement bupropion switch or augmentation strategy
Critical Safety Monitoring
- Serotonin syndrome risk: Combining multiple serotonergic agents (mirtazapine + any SSRI/SNRI if added) requires monitoring for agitation, confusion, tremor, hyperthermia 1
- Suicidality monitoring: Increased risk in first 1-2 months of any antidepressant change 10
- Avoid abrupt discontinuation: Taper any medication changes over 10-14 days to prevent withdrawal 1
Why Not Continue Current Regimen
Your current polypharmacy with subtherapeutic dosing represents a common pitfall in treatment-resistant depression. The evidence clearly shows that switching or optimizing is superior to simply adding more medications 10, 3. With inadequate mirtazapine dosing, minimal methylphenidate, and buspirone with limited evidence, you're receiving the side effects of multiple medications without therapeutic benefit.
The STAR*D trial demonstrated that after two failed antidepressant trials, remission rates with a third medication are low (<20%) 11, making optimization of current therapy and strategic medication selection critical rather than continued polypharmacy.